Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
F 1.83 2.23% 0.04
CLBS closed up 2.23 percent on Monday, March 8, 2021, on 69 percent of normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CLBS trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 2.23%
Inside Day Range Contraction 2.23%
Wide Bands Range Expansion 2.23%
Lower Bollinger Band Touch Weakness 2.23%
Fell Below 200 DMA Bearish 0.55%
Hammer Candlestick Bullish 0.55%
Earnings Movers Other 0.55%
Older End-of-Day Signals for CLBS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 12 hours ago
Gap Up Closed about 14 hours ago
Gap Up Partially Closed about 14 hours ago
2x Volume Pace about 14 hours ago
1.5x Volume Pace about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Caladrius Biosciences, Inc. Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Banking Biopharmaceutical Cancer Immunotherapy Diabetes Cancer Immunotherapy Melanoma Cell Therapy Clinical Services Adult Stem Cell Immunotherapy Product Progenitor Cell Cord Blood Metastatic Melanoma Cancer Immunotherapy Product Infarction Myocardial Infarction Neos Acute Myocardial Infarction Treatment Of Metastatic Melanoma

Is CLBS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.88
52 Week Low 1.05
Average Volume 6,872,374
200-Day Moving Average 1.89
50-Day Moving Average 1.96
20-Day Moving Average 2.11
10-Day Moving Average 1.88
Average True Range 0.29
ADX 19.55
+DI 27.59
-DI 25.48
Chandelier Exit (Long, 3 ATRs ) 2.18
Chandelier Exit (Short, 3 ATRs ) 2.39
Upper Bollinger Band 2.64
Lower Bollinger Band 1.59
Percent B (%b) 0.23
BandWidth 49.74
MACD Line -0.07
MACD Signal Line -0.02
MACD Histogram -0.0531
Fundamentals Value
Market Cap 35.49 Million
Num Shares 19.4 Million
EPS -1.87
Price-to-Earnings (P/E) Ratio -0.98
Price-to-Sales 0.00
Price-to-Book 0.75
PEG Ratio -0.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.15
Resistance 3 (R3) 2.16 2.07 2.09
Resistance 2 (R2) 2.07 1.99 2.06 2.07
Resistance 1 (R1) 1.95 1.94 1.91 1.94 2.06
Pivot Point 1.86 1.86 1.84 1.85 1.86
Support 1 (S1) 1.74 1.78 1.70 1.73 1.60
Support 2 (S2) 1.65 1.73 1.64 1.59
Support 3 (S3) 1.53 1.65 1.57
Support 4 (S4) 1.52